Despite intensive immunosuppressant therapy following lung transplantation, acute rejection occurs in over 50% of recipients within the first 6 months. Bronchiolitis obliterans syndrome (BOS) is related to acute rejection and independently contributes to mortality. It is thought that T cell depleting agents might reduce the incidence of these complications. Alemtuzumab is a humanised monoclonal antibody to the CD52 antigen which is expressed on T …